Author

R. Rosales

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:drug response / drug discovery· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Assay:bulk RNA-seq· 1 Organism:multiple species· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Garcia-Sastre· 3 shared K. M. White· 2 shared A. Fabro· 1 shared A. S. Anderson· 1 shared A.-K. Reuschl· 1 shared B. Harish· 1 shared B. L. McGovern· 1 shared C. A. Royer· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

A. Garcia-Sastre

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Nirmatrelvir, Molnupiravir, and Remdesivir maintain potent in vitro activity against the SARS-CoV-2 Omicron variant

R. Rosales, B. L. McGovern, M. L. Rodriquez, D. K. Rai, R. D. Cardin, A. S. Anderson, E. M. Sordillo, H. van Bakel, V. Simon, A. Garcia-Sastre, K. M. White

This study evaluates the antiviral activity of nirmatrelvir, molnupiravir, and remdesivir against the SARS-CoV-2 Omicron variant and confirms their potency.

bioRxiv · Jan 17, 2022 · PreprintMicrobiology

The dengue virus non-structural protein 1 (NS1) interacts with the putative epigenetic regulator DIDO1 to promote flavivirus replication.

g. caraballo, R. Rosales, M. Viettri, S. Ding, H. B. Greenberg, J. Ludert

This study identifies DIDO1 as a host factor interacting with DENV NS1 to promote flavivirus replication in mosquito cells.

bioRxiv · Sep 1, 2021 · PreprintMicrobiology

Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant

A.-K. Reuschl, L. Thorne, L. Zuliani Alvarez, M. Bouhaddou, K. Obernier, J. Hiatt, M. Soucheray, J. Turner, J. Fabius, G. T. Nguyen, D. Swaney, R. Rosales, K. M. White, P. Aviles, I. T. Kirby, , N. J. Krogan

This study evaluates the efficacy of host-directed therapies against the B.1.1.7 SARS-CoV-2 variant and finds similar antiviral activity compared to early-lineage SARS-CoV-2.

bioRxiv · Jan 24, 2021 · PreprintMicrobiology

Hepatitis C Virus Drugs Simeprevir and Grazoprevir Synergize with Remdesivir to Suppress SARS-CoV-2 Replication in Cell Culture

K. Bafna, K. White, B. Harish, R. Rosales, T. A. Ramelot, T. B. Acton, E. Moreno, T. Kehrer, C. A. Royer, A. Garcia-Sastre, R. M. Krug, G. T. Montelione

This paper evaluates HCV protease inhibitors as potential SARS-CoV-2 antivirals, finding that simeprevir and grazoprevir synergize with remdesivir to enhance antiviral activity against SARS-CoV-2 in cell culture.

bioRxiv · Dec 13, 2020Biochemistry

Infection of human lymphomononuclear cells by SARS-CoV-2

M. C. Pontelli, I. A. Castro, R. B. Martins, F. P. Veras, L. La Serra, D. C. Nascimento, R. S. Cardoso, R. Rosales, T. M. Lima, J. P. Souza, D. B. Caetite, M. H. Lima, J. T. Kawahisa, M. C. Giannini, L. P. Bonjorno, , E. Arruda

This study investigates SARS-CoV-2 infection of human lymphomononuclear cells in vitro and in vivo, finding that monocytes, B cells, and T cells are susceptible to infection and viral replication.

bioRxiv · Jul 28, 2020Microbiology